The Phase 1 GALLOP study evaluating the investigational CAR-T therapy, CB-010, for treatment of lupus nephritis has launched.

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor ...

Researchers have discovered that mouse PD-1 is significantly weaker than human PD-1, calling into question their reliability ...

Megakaryocytes (MKs), which are traditionally known for their role in platelet production, are now emerging as unique immune ...

A study explores the molecular dynamics of CD28.ζ-CAR and 4-1BB.ζ-CAR T cells at the immune synapse, where CAR T cells bind ...

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor ...

A groundbreaking study from Baylor College of Medicine explores how two types of CAR T cells target cancer, shedding light on ...

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with ...

Caribou Biosciences has launched a Phase 1 trial testing its CAR T-cell therapy CB-010 for lupus affecting the kidneys and ...

Verismo Therapeutics, a subsidiary of HLB Innovation, announced on Jan. 13 that it has completed the first patient administration of its next-generation chimeric antigen receptor T-cell ... with ...

Rese-cel, previously called CABA-201, is a CAR T-cell therapy that's designed to treat MS by depleting B-cells.

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon WARMINSTER, Pa., Jan. 13, 2025 (GLOBE ...